JPMorgan upgraded Edwards Lifesciences (EW) to Overweight from Neutral with a price target of $100, up from $90. The firm sees good visibility into share outperformance in 2026 for Edwards. The company’s “robust” innovation pipeline should support sustainable premium growth over the longer term, the analyst tells investors in a research note. JPMorgan believes the company provided “conservative” 2026 guidance that is beatable as transcatheter aortic valve replacement continues to accelerate.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences: Buy Rating on Structural Heart Leadership, Accelerating TAVR/TMTT Growth, and Durable Double‑Digit Upside
- Edwards Lifesciences price target lowered to $87 from $89 at Canaccord
- Positive Outlook for Edwards Lifesciences Amid CMS Coverage Expansion for TAVR Procedures
- Buy Rating for Edwards Lifesciences Amid Potential TAVR Coverage Expansion and Strategic Alignment
- Edwards Lifesciences: Buy Rating Backed by Strategic Initiatives and Expanding Market Potential